Physician profile
Connie Lea Calvert
NPI 1770757775
$6,127.90
in general payments reported to CMS, 2019-2025
17 companies · $16.24 in 2025
The $16.24 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $941 · 2021: $1,506 · 2022: $1,319 · 2023: $864 · 2024: $115 · 2025: $16.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.60 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,385.98 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $896.05 | 2019-2024 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $775.73 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $672.71 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $497.62 | 2019-2023 | Ingrezza |
| Janssen Pharmaceuticals, INC | $458.78 | 2019-2023 | Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $407.62 | 2019-2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $287.18 | 2020-2024 | Caplyta |
| Lundbeck LLC | $209.07 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $194.36 | 2019-2022 | |
| Indivior INC. | $80.26 | 2022-2024 | Perseris |
| Allergan, INC. | $63.99 | 2019-2020 | |
| Coloplast Corp | $61.25 | 2022 | |
| Eisai INC. | $54.94 | 2020-2021 | |
| Noven Therapeutics, LLC | $42.34 | 2020-2023 | Secuado |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Calvert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.